A HIV/AIDS clinical trial begins in China.
A HIV/AIDS clinical trial begins in China.
The research company Guangzhou 8th People's Hospital is conducting the clinical trial The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART.
To evaluate the safety and efficacy of arsenic trioxide combined with cART in eliminating latent HIV-1 reservoir, providing potential strategies for AIDS functional cure.
It is planned to include 20 participants.
Actual study start date is April 1, 2019. The researchers expect to complete the study by December 31, 2021.
One primary outcome measure is Incidence of treatment-emergent adverse events of arsenic trioxide combined with cART, To observe the adverse events of arsenic trioxide combined with cART when treating with HIV-infected patients during the clinical trial.
Inclusion Criteria: 1. HIV infection confirmed 2. Receiving HAART more than 12 months. 3. HIV viral-load < 50 copies/ml and CD4+ cell count more than 350 cells/ul. 4. Without serious heart, lung, liver or kidney disease. 5. Participants know about the study and sign informed consent. Exclusion Criteria: 1. With serious active HBV or HCV infection or opportunistic infections 2. With serious chronic disease such as diabetes, mental illness,et al 3. History of suffering from pancreatitis during HAART. 4. Pregnant or breast-fed. 5. With poor adherence. 6. Unable to complete the follow up.
The location of the study is as follows (further details can be found here: https://ichgcp.net/clinical-trials-registry/NCT03980665
